

# Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.3	85.9	(37.0-169.3)	Male	4	6.3	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	88.6	(28.5-206.6)
Female	41	34.5	118.8	(85.2-161.2)	Female	7	3.9	180.3	(72.2-371.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	5	4.9	101.5	(32.7-236.9)
<b><u>Colon / Rectum</u></b>					Female	4	1.7	nc	(nc-nc)
Male	10	10.4	95.8	(45.9-176.2)	<b><u>Ovary</u></b>				
Female	6	7.9	75.8	(27.7-164.9)	Female	3	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	45	35.7	126.1	(92.0-168.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.3	nc	(nc-nc)
Male	6	5.7	105.7	(38.6-230.0)	Female	1	1.0	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.4	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	7.0	85.4	(31.2-185.9)
Male	2	3.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	11	7.9	139.5	(69.5-249.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	130	131.4	98.9	(82.6-117.5)
Female	1	0.9	nc	(nc-nc)	Female	137	109.5	125.1	(105.0-147.9)
<b><u>Lung and Bronchus</u></b>									
Male	19	17.3	110.1	(66.2-171.9)					
Female	25	14.4	174.2	(112.7-257.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	22.1	90.5	(55.3-139.8)	Male	6	14.3	41.9	(15.3-91.1)
Female	9	8.5	105.4	(48.1-200.0)	Female	7	11.3	62.0	(24.8-127.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	6	3.5	171.1	(62.5-372.3)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	9	12.9	69.9	(31.9-132.8)
Female	72	85.7	84.0	(65.7-105.8)	Female	13	11.5	112.9	(60.1-193.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	12	10.2	117.1	(60.4-204.5)
<b><u>Colon / Rectum</u></b>					Female	4	4.7	nc	(nc-nc)
Male	24	24.2	99.3	(63.6-147.8)	<b><u>Ovary</u></b>				
Female	26	25.7	101.1	(66.0-148.2)	Female	7	7.7	90.4	(36.2-186.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	5.8	172.3	(82.5-316.9)	Male	8	7.7	103.7	(44.7-204.4)
Female	2	1.6	nc	(nc-nc)	Female	8	8.7	92.1	(39.7-181.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	67	71.4	93.8	(72.7-119.1)
Female	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	5.2	nc	(nc-nc)
Male	17	12.1	140.8	(82.0-225.4)	Female	5	3.4	149.1	(48.0-347.9)
Female	8	7.0	114.3	(49.2-225.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.3	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	15.3	78.3	(40.4-136.9)
Male	11	8.9	123.2	(61.4-220.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	6.8	160.6	(80.1-287.5)	Female	22	19.3	114.1	(71.5-172.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	7.7	130.6	(62.5-240.2)	Male	285	288.2	98.9	(87.7-111.1)
Female	3	2.6	nc	(nc-nc)	Female	299	301.1	99.3	(88.4-111.2)
<b><u>Lung and Bronchus</u></b>									
Male	53	38.9	136.3	(102.1-178.3)					
Female	49	43.0	113.8	(84.2-150.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	8.8	nc	(nc-nc)	Male	8	5.8	136.8	(58.9-269.5)
Female	1	2.8	nc	(nc-nc)	Female	5	4.3	115.4	(37.2-269.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.2	172.2	(78.6-327.0)
Female	33	35.7	92.5	(63.7-129.9)	Female	2	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.8	nc	(nc-nc)
Male	6	9.8	61.1	(22.3-132.9)	<b><u>Ovary</u></b>				
Female	7	8.4	83.6	(33.5-172.3)	Female	0	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	36	32.1	112.3	(78.6-155.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.1	nc	(nc-nc)
Male	7	5.2	134.0	(53.7-276.2)	Female	1	1.0	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.1	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.7	74.7	(24.1-174.2)
Male	2	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.3	nc	(nc-nc)	Female	12	8.3	144.5	(74.6-252.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	101	120.6	83.7	(68.2-101.8)
Female	1	0.9	nc	(nc-nc)	Female	114	114.1	99.9	(82.4-120.0)
<b><u>Lung and Bronchus</u></b>									
Male	7	16.3	43.1	(17.3-88.7)					
Female	20	15.6	127.8	(78.0-197.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gill

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	8	7.3	109.9	(47.3-216.6)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.4	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	9	7.6	117.8	(53.8-223.7)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	26	26.3	98.8	(64.5-144.8)
Female	0	0.2	nc	(nc-nc)	Female	28	23.4	119.7	(79.5-173.1)
<b><u>Lung and Bronchus</u></b>									
Male	7	3.4	205.3	(82.2-423.0)					
Female	6	3.2	189.6	(69.2-412.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	39.0	107.8	(77.7-145.7)	Male	29	24.4	118.7	(79.5-170.5)
Female	23	14.7	156.8	(99.3-235.3)	Female	23	19.4	118.8	(75.3-178.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	6.9	nc	(nc-nc)	Male	9	7.8	114.9	(52.4-218.1)
Female	5	5.9	84.2	(27.1-196.4)	Female	2	6.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	24	21.7	110.4	(70.7-164.3)
Female	168	157.5	106.6	(91.1-124.0)	Female	21	20.1	104.7	(64.8-160.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.9	nc	(nc-nc)	Male	21	18.0	116.8	(72.3-178.6)
<b><u>Colon / Rectum</u></b>					Female	11	8.5	129.9	(64.7-232.4)
Male	43	40.7	105.7	(76.5-142.3)	<b><u>Ovary</u></b>				
Female	35	43.1	81.3	(56.6-113.0)	Female	18	14.0	128.9	(76.3-203.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	10.6	141.4	(79.1-233.2)	Male	22	13.8	159.1	(99.7-241.0)
Female	2	2.8	nc	(nc-nc)	Female	12	14.6	82.2	(42.4-143.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	141	140.9	100.1	(84.2-118.0)
Female	4	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	9.1	110.1	(52.7-202.5)
Male	16	21.3	75.3	(43.0-122.2)	Female	2	5.5	nc	(nc-nc)
Female	17	12.6	134.5	(78.3-215.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.8	nc	(nc-nc)
Male	8	6.3	127.7	(55.0-251.7)	<b><u>Thyroid</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	10	8.9	112.7	(53.9-207.2)
<b><u>Leukemia</u></b>					Female	33	25.9	127.6	(87.8-179.2)
Male	21	14.9	141.3	(87.4-216.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	11.3	79.8	(36.4-151.5)	Female	28	36.9	75.8	(50.4-109.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	13.4	74.4	(35.6-136.8)	Male	565	514.6	109.8	(100.9-119.2)
Female	6	4.7	128.7	(47.0-280.0)	Female	562	533.9	105.3	(96.7-114.3)
<b><u>Lung and Bronchus</u></b>									
Male	87	71.1	122.4	(98.0-151.0)					
Female	100	78.3	127.6	(103.8-155.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	3	5.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.0	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	12	16.1	74.5	(38.5-130.2)
Female	0	0.2	nc	(nc-nc)	Female	8	18.3	43.8	(18.8-86.2)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.2	nc	(nc-nc)					
Female	0	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	4.6	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Grafton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	15.3	117.8	(69.8-186.2)	Male	9	10.6	85.2	(38.9-161.7)
Female	4	5.2	nc	(nc-nc)	Female	10	8.6	116.7	(55.9-214.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	3.5	315.5	(157.3-564.6)	Male	4	3.2	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	4	9.5	nc	(nc-nc)
Female	80	65.9	121.3	(96.2-151.0)	Female	11	7.7	142.2	(70.9-254.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	17	7.9	214.6	(124.9-343.6)
<b><u>Colon / Rectum</u></b>					Female	3	3.3	nc	(nc-nc)
Male	14	17.6	79.4	(43.3-133.1)	<b><u>Ovary</u></b>				
Female	22	16.2	136.0	(85.2-205.9)	Female	6	5.7	104.4	(38.1-227.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.2	119.6	(38.6-279.2)	Male	4	5.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	59	52.4	112.6	(85.7-145.3)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.7	nc	(nc-nc)
Male	11	9.2	119.9	(59.8-214.5)	Female	1	2.1	nc	(nc-nc)
Female	5	5.1	98.9	(31.9-230.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.8	nc	(nc-nc)
Male	6	2.5	243.6	(89.0-530.3)	<b><u>Thyroid</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	7	4.6	152.6	(61.2-314.5)
<b><u>Leukemia</u></b>					Female	13	13.9	93.4	(49.7-159.7)
Male	12	6.7	179.0	(92.4-312.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	4.6	216.4	(103.6-397.9)	Female	13	14.7	88.7	(47.2-151.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	5.8	103.5	(37.8-225.3)	Male	235	211.0	111.4	(97.6-126.6)
Female	0	1.7	nc	(nc-nc)	Female	248	215.2	115.2	(101.3-130.5)
<b><u>Lung and Bronchus</u></b>									
Male	34	27.4	123.9	(85.8-173.1)					
Female	35	28.5	122.7	(85.5-170.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.7	74.6	(24.0-174.0)	Male	1	4.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.9	154.7	(56.5-336.7)
Female	18	32.6	55.3	(32.8-87.4)	Female	3	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	9	7.2	124.4	(56.8-236.1)	<b><u>Ovary</u></b>				
Female	6	8.7	69.2	(25.3-150.7)	Female	5	2.9	174.8	(56.3-407.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	18	23.0	78.2	(46.3-123.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.8	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	11	7.4	149.2	(74.4-267.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	79	89.0	88.7	(70.2-110.6)
Female	1	0.9	nc	(nc-nc)	Female	82	107.5	76.3	(60.7-94.7)
<b><u>Lung and Bronchus</u></b>									
Male	13	11.9	109.2	(58.1-186.8)					
Female	13	14.7	88.5	(47.1-151.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	7	7.7	91.2	(36.5-188.0)	Female	0	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	10	8.4	118.9	(56.9-218.7)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	1.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	32	30.1	106.1	(72.6-149.9)
Female	0	0.2	nc	(nc-nc)	Female	26	24.7	105.1	(68.6-154.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	4.1	nc	(nc-nc)					
Female	5	3.5	141.4	(45.6-330.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	8.4	142.7	(73.6-249.2)	Male	9	5.2	172.4	(78.7-327.3)
Female	9	3.9	230.8	(105.3-438.1)	Female	3	4.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	39	36.8	106.1	(75.5-145.1)	Female	5	5.1	98.4	(31.7-229.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.1	nc	(nc-nc)
Male	8	8.9	90.2	(38.8-177.8)	<b><u>Ovary</u></b>				
Female	10	11.5	87.2	(41.7-160.4)	Female	3	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	4.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	32	25.3	126.7	(86.6-178.9)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.9	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	5.7	158.4	(72.3-300.6)
Male	3	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.9	nc	(nc-nc)	Female	7	8.4	83.1	(33.3-171.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	115	104.7	109.9	(90.7-131.9)
Female	1	1.2	nc	(nc-nc)	Female	131	131.0	100.0	(83.6-118.7)
<b><u>Lung and Bronchus</u></b>									
Male	14	14.3	97.9	(53.5-164.2)					
Female	21	19.7	106.5	(65.9-162.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	20.2	94.0	(56.6-146.8)	Male	13	13.0	100.1	(53.2-171.1)
Female	5	8.0	62.5	(20.1-145.9)	Female	5	10.7	46.6	(15.0-108.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.8	130.4	(42.0-304.4)	Male	4	4.1	nc	(nc-nc)
Female	7	3.3	214.9	(86.1-442.9)	Female	3	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	5	11.5	43.4	(14.0-101.3)
Female	74	82.8	89.4	(70.2-112.2)	Female	13	10.8	119.9	(63.8-205.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.7	nc	(nc-nc)	Male	9	9.4	95.5	(43.6-181.3)
<b><u>Colon / Rectum</u></b>					Female	3	4.5	nc	(nc-nc)
Male	28	21.7	129.2	(85.8-186.7)	<b><u>Ovary</u></b>				
Female	26	24.3	107.0	(69.9-156.7)	Female	9	7.4	120.9	(55.2-229.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	7	7.1	97.9	(39.2-201.8)
Female	1	1.5	nc	(nc-nc)	Female	5	8.1	61.5	(19.8-143.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	1.5	412.8	(150.8-898.6)	Male	46	69.1	66.6	(48.7-88.8)
Female	3	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.8	nc	(nc-nc)
Male	6	11.0	54.6	(20.0-118.9)	Female	3	3.2	nc	(nc-nc)
Female	6	6.7	90.2	(32.9-196.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.7	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	14.7	nc	(nc-nc)
Male	3	8.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.4	94.4	(34.5-205.5)	Female	21	18.7	112.6	(69.6-172.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	7.2	69.1	(22.3-161.2)	Male	222	266.3	83.4	(72.7-95.1)
Female	5	2.5	203.8	(65.7-475.5)	Female	273	286.4	95.3	(84.4-107.3)
<b><u>Lung and Bronchus</u></b>									
Male	33	36.2	91.1	(62.7-127.9)					
Female	44	40.4	109.0	(79.2-146.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	9.5	125.8	(64.9-219.8)	Male	3	6.9	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	38	45.1	84.3	(59.6-115.6)	Female	4	4.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	5	5.6	89.1	(28.7-208.0)
<b><u>Colon / Rectum</u></b>					Female	1	2.2	nc	(nc-nc)
Male	16	11.4	140.8	(80.4-228.7)	<b><u>Ovary</u></b>				
Female	9	9.8	91.5	(41.7-173.6)	Female	2	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	31	38.4	80.6	(54.8-114.5)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.4	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	1.4	486.1	(194.7-1001.6)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	8.8	79.4	(31.8-163.5)
Male	5	4.2	120.0	(38.7-280.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.7	nc	(nc-nc)	Female	10	10.3	97.1	(46.5-178.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.1	nc	(nc-nc)	Male	128	141.8	90.3	(75.3-107.4)
Female	2	1.1	nc	(nc-nc)	Female	104	138.7	75.0	(61.3-90.9)
<b><u>Lung and Bronchus</u></b>									
Male	11	18.1	60.8	(30.3-108.7)					
Female	10	17.9	56.0	(26.8-103.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	8.0	99.9	(43.0-196.9)	Male	6	5.1	117.1	(42.8-254.9)
Female	2	2.7	nc	(nc-nc)	Female	11	3.9	281.5	(140.3-503.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.6	174.3	(75.1-343.5)
Female	39	32.6	119.5	(85.0-163.4)	Female	6	3.9	155.2	(56.7-337.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.7	nc	(nc-nc)
Male	4	8.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	9	8.0	112.6	(51.4-213.8)	Female	3	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	24	26.9	89.3	(57.2-132.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.9	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	Female	4	1.0	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	5.6	179.8	(86.1-330.7)
Male	2	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.2	nc	(nc-nc)	Female	4	7.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	90	104.9	85.8	(69.0-105.4)
Female	1	0.9	nc	(nc-nc)	Female	125	106.1	117.8	(98.1-140.4)
<b><u>Lung and Bronchus</u></b>									
Male	11	14.5	76.1	(37.9-136.1)					
Female	17	15.1	112.8	(65.7-180.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	6.8	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
Female	6	3.2	187.4	(68.4-408.0)	Female	3	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.7	188.3	(75.4-388.0)
Female	28	29.4	95.2	(63.3-137.6)	Female	7	4.1	170.1	(68.1-350.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	7	2.9	240.6	(96.4-495.7)
<b><u>Colon / Rectum</u></b>					Female	0	1.7	nc	(nc-nc)
Male	5	7.0	70.9	(22.9-165.6)	<b><u>Ovary</u></b>				
Female	10	9.2	108.9	(52.1-200.3)	Female	2	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	19	22.1	86.1	(51.8-134.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.4	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.4	nc	(nc-nc)	Female	9	6.9	131.3	(59.9-249.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	71	85.9	82.6	(64.5-104.2)
Female	1	0.9	nc	(nc-nc)	Female	92	105.6	87.1	(70.2-106.8)
<b><u>Lung and Bronchus</u></b>									
Male	6	12.1	49.7	(18.1-108.1)					
Female	9	16.2	55.7	(25.4-105.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Halifax

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.1	98.9	(39.6-203.7)	Male	5	5.0	100.8	(32.5-235.2)
Female	2	3.2	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.5	112.3	(36.2-262.0)
Female	38	35.6	106.6	(75.5-146.4)	Female	7	4.4	158.5	(63.5-326.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.9	nc	(nc-nc)
Male	13	8.3	156.0	(83.0-266.8)	<b><u>Ovary</u></b>				
Female	12	9.6	124.5	(64.2-217.4)	Female	4	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	8	2.6	308.4	(132.8-607.7)
Female	0	0.6	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	36	26.7	134.9	(94.5-186.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	8	4.5	178.4	(76.8-351.5)	Female	1	1.2	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	6	2.2	277.3	(101.3-603.6)
<b><u>Leukemia</u></b>					Female	11	6.2	177.0	(88.2-316.7)
Male	2	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	12	7.9	152.6	(78.8-266.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	2.8	180.6	(58.2-421.5)	Male	143	101.2	141.3	(119.1-166.5)
Female	1	1.0	nc	(nc-nc)	Female	135	119.0	113.5	(95.2-134.3)
<b><u>Lung and Bronchus</u></b>									
Male	22	13.3	165.6	(103.8-250.8)					
Female	20	17.1	116.7	(71.3-180.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.7	77.8	(28.4-169.3)	Male	3	5.1	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	5	4.3	117.0	(37.7-273.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	5	1.6	312.8	(100.8-729.9)
Female	3	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	131.1	(47.9-285.4)
Female	32	33.9	94.4	(64.5-133.2)	Female	8	4.2	191.2	(82.3-376.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	5	3.7	134.8	(43.4-314.5)
<b><u>Colon / Rectum</u></b>					Female	2	1.8	nc	(nc-nc)
Male	6	8.5	70.6	(25.8-153.8)	<b><u>Ovary</u></b>				
Female	10	8.9	111.8	(53.5-205.6)	Female	2	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	24	26.3	91.3	(58.5-135.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	7	4.4	158.5	(63.5-326.7)	Female	0	1.1	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	5	2.1	241.5	(77.8-563.5)
<b><u>Leukemia</u></b>					Female	8	6.2	129.7	(55.8-255.6)
Male	6	3.3	184.3	(67.3-401.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.4	nc	(nc-nc)	Female	7	7.7	90.8	(36.4-187.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	107	103.6	103.3	(84.7-124.8)
Female	0	1.0	nc	(nc-nc)	Female	114	113.3	100.6	(83.0-120.9)
<b><u>Lung and Bronchus</u></b>									
Male	13	14.0	93.0	(49.5-159.0)					
Female	11	16.1	68.5	(34.1-122.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	8.6	70.0	(25.6-152.3)	Male	2	5.2	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	130.5	(47.7-284.1)
Female	23	26.6	86.4	(54.7-129.6)	Female	1	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.4	nc	(nc-nc)
Male	2	8.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	7.1	70.1	(22.6-163.6)	Female	1	2.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	5	2.9	170.9	(55.1-398.7)
Female	0	0.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	21	28.2	74.4	(46.1-113.8)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.9	nc	(nc-nc)
Male	5	4.4	114.3	(36.8-266.8)	Female	2	0.9	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.4	113.9	(36.7-265.8)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	87	107.5	80.9	(64.8-99.8)
Female	0	0.8	nc	(nc-nc)	Female	67	89.1	75.2	(58.3-95.5)
<b><u>Lung and Bronchus</u></b>									
Male	15	15.5	96.5	(54.0-159.2)					
Female	8	12.9	61.9	(26.6-122.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	9.2	87.2	(37.5-171.8)
Female	0	0.1	nc	(nc-nc)	Female	8	10.2	78.8	(33.9-155.2)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.2	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	13.6	88.0	(45.4-153.8)	Male	15	9.1	165.0	(92.3-272.1)
Female	4	4.9	nc	(nc-nc)	Female	5	7.3	68.8	(22.2-160.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.9	173.1	(55.8-404.0)	Male	2	2.9	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	5	2.2	224.2	(72.3-523.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	8	8.2	98.0	(42.2-193.0)
Female	78	58.2	134.0	(105.9-167.2)	Female	10	7.0	143.3	(68.6-263.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	6	6.8	88.1	(32.2-191.7)
<b><u>Colon / Rectum</u></b>					Female	1	3.0	nc	(nc-nc)
Male	15	15.1	99.1	(55.4-163.4)	<b><u>Ovary</u></b>				
Female	17	14.6	116.2	(67.7-186.1)	Female	4	5.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	1	4.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	69	47.8	144.4	(112.3-182.8)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.3	nc	(nc-nc)
Male	4	8.0	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	5	4.5	111.0	(35.8-259.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	5	2.2	228.8	(73.7-533.8)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	8	3.7	213.6	(92.0-420.8)
<b><u>Leukemia</u></b>					Female	10	11.0	90.9	(43.5-167.2)
Male	6	5.7	104.4	(38.1-227.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	4.1	nc	(nc-nc)	Female	19	13.3	142.7	(85.8-222.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	198	185.5	106.7	(92.4-122.7)
Female	0	1.6	nc	(nc-nc)	Female	207	191.2	108.3	(94.0-124.1)
<b><u>Lung and Bronchus</u></b>									
Male	21	24.7	85.0	(52.6-130.0)					
Female	27	26.2	102.9	(67.8-149.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.2	119.5	(59.6-213.8)	Male	4	6.5	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	5	4.9	102.2	(32.9-238.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	31	40.8	75.9	(51.6-107.8)	Female	5	4.4	114.4	(36.9-267.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	9	5.2	173.7	(79.3-329.7)
<b><u>Colon / Rectum</u></b>					Female	1	1.9	nc	(nc-nc)
Male	13	10.7	121.9	(64.8-208.4)	<b><u>Ovary</u></b>				
Female	12	8.5	140.7	(72.6-245.9)	Female	4	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	5	3.4	145.3	(46.8-339.1)
Female	1	0.6	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	39	37.7	103.6	(73.6-141.6)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.3	nc	(nc-nc)
Male	4	6.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	5	3.0	167.0	(53.8-389.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.5	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.2	121.2	(58.0-223.0)
Male	4	4.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.5	nc	(nc-nc)	Female	15	9.3	161.3	(90.2-266.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.7	135.6	(43.7-316.4)	Male	143	135.5	105.5	(88.9-124.3)
Female	3	1.0	nc	(nc-nc)	Female	127	125.8	100.9	(84.1-120.1)
<b><u>Lung and Bronchus</u></b>									
Male	26	17.3	150.0	(98.0-219.8)					
Female	17	16.5	102.8	(59.8-164.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	12	14.3	83.7	(43.2-146.2)	Female	2	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	4	4.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	15.3	45.8	(18.3-94.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.5	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	37	59.6	62.0	(43.7-85.5)
Female	0	0.4	nc	(nc-nc)	Female	34	47.4	71.7	(49.6-100.2)
<b><u>Lung and Bronchus</u></b>									
Male	6	8.6	70.0	(25.6-152.5)					
Female	6	6.6	90.3	(33.0-196.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	8.4	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.2	153.6	(66.1-302.7)
Female	20	24.1	83.0	(50.7-128.2)	Female	2	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.2	nc	(nc-nc)
Male	4	9.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	9	5.6	160.3	(73.1-304.3)	Female	2	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	22	33.3	66.1	(41.4-100.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.1	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.3	115.8	(37.3-270.2)
Male	4	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.5	nc	(nc-nc)	Female	6	5.5	108.9	(39.8-237.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.4	nc	(nc-nc)	Male	74	121.3	61.0	(47.9-76.6)
Female	0	0.6	nc	(nc-nc)	Female	57	76.4	74.6	(56.5-96.7)
<b><u>Lung and Bronchus</u></b>									
Male	5	15.9	31.5	(10.2-73.6)					
Female	5	10.8	46.3	(14.9-108.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	21.3	121.8	(79.6-178.5)	Male	18	12.4	145.5	(86.2-230.0)
Female	10	8.3	121.0	(57.9-222.6)	Female	19	9.7	196.5	(118.3-306.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.2	nc	(nc-nc)	Male	6	4.0	149.7	(54.7-325.8)
Female	2	3.0	nc	(nc-nc)	Female	6	3.6	165.6	(60.5-360.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	15	10.8	138.5	(77.5-228.5)
Female	102	79.1	128.9	(105.1-156.5)	Female	10	10.8	92.9	(44.5-170.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	10	8.0	125.4	(60.0-230.6)
<b><u>Colon / Rectum</u></b>					Female	3	4.4	nc	(nc-nc)
Male	21	20.8	101.1	(62.6-154.6)	<b><u>Ovary</u></b>				
Female	32	23.4	136.5	(93.3-192.7)	Female	7	7.1	98.6	(39.5-203.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.2	115.2	(42.1-250.7)	Male	9	7.2	125.8	(57.4-238.9)
Female	2	1.6	nc	(nc-nc)	Female	10	8.3	120.8	(57.8-222.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	1.0	496.7	(160.1-1159.2)	Male	100	64.7	154.5	(125.7-187.9)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	4.7	170.3	(73.3-335.6)
Male	9	9.9	90.9	(41.5-172.5)	Female	2	3.0	nc	(nc-nc)
Female	8	6.6	121.1	(52.1-238.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.5	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	5	3.7	135.3	(43.6-315.8)
<b><u>Leukemia</u></b>					Female	2	11.3	nc	(nc-nc)
Male	9	7.6	117.7	(53.7-223.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	6.0	nc	(nc-nc)	Female	18	18.8	95.8	(56.8-151.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.2	nc	(nc-nc)	Male	326	254.2	128.2	(114.7-142.9)
Female	2	2.5	nc	(nc-nc)	Female	311	278.6	111.6	(99.6-124.8)
<b><u>Lung and Bronchus</u></b>									
Male	47	38.2	123.2	(90.5-163.8)					
Female	39	43.5	89.7	(63.8-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.5	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	15	18.9	79.2	(44.3-130.6)	Female	1	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	5	5.0	100.8	(32.5-235.1)	<b><u>Ovary</u></b>				
Female	9	4.9	182.2	(83.2-346.0)	Female	4	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	16.4	121.7	(74.3-187.9)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	5	1.5	338.6	(109.1-790.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.1	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	5	4.4	114.9	(37.0-268.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	60	60.5	99.1	(75.7-127.6)
Female	0	0.5	nc	(nc-nc)	Female	57	62.7	91.0	(68.9-117.9)
<b><u>Lung and Bronchus</u></b>									
Male	7	8.4	83.2	(33.3-171.4)					
Female	4	9.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	57	59.1	96.4	(73.0-124.9)	Male	24	38.7	62.0	(39.7-92.3)
Female	27	21.7	124.5	(82.0-181.1)	Female	20	32.3	61.9	(37.8-95.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	12.1	115.8	(63.3-194.4)	Male	10	11.9	84.0	(40.2-154.6)
Female	11	10.1	109.0	(54.3-195.0)	Female	8	9.8	81.4	(35.1-160.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	40	34.9	114.8	(82.0-156.3)
Female	255	244.4	104.3	(91.9-117.9)	Female	41	30.7	133.5	(95.8-181.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	8.8	nc	(nc-nc)	Male	39	28.0	139.0	(98.9-190.1)
<b><u>Colon / Rectum</u></b>					Female	16	12.9	123.7	(70.6-200.8)
Male	77	65.7	117.3	(92.5-146.6)	<b><u>Ovary</u></b>				
Female	67	67.7	99.0	(76.7-125.8)	Female	20	21.9	91.3	(55.8-141.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	15.5	77.2	(39.9-134.9)	Male	25	20.9	119.7	(77.5-176.8)
Female	4	4.2	nc	(nc-nc)	Female	28	22.0	127.0	(84.4-183.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	5.0	119.5	(43.6-260.0)	Male	165	194.1	85.0	(72.5-99.0)
Female	3	4.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	14.0	142.6	(87.1-220.2)
Male	32	32.8	97.6	(66.8-137.8)	Female	6	8.7	68.8	(25.1-149.7)
Female	24	19.2	124.8	(79.9-185.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	9.7	72.5	(29.1-149.4)
Male	9	9.0	100.4	(45.8-190.6)	<b><u>Thyroid</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	16	15.7	101.8	(58.2-165.4)
<b><u>Leukemia</u></b>					Female	56	48.3	115.9	(87.6-150.6)
Male	22	24.6	89.5	(56.1-135.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	19	18.6	102.0	(61.4-159.4)	Female	58	54.8	105.8	(80.3-136.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	20.6	87.2	(51.7-137.9)	Male	749	780.4	96.0	(89.2-103.1)
Female	4	6.9	nc	(nc-nc)	Female	896	827.6	108.3	(101.3-115.6)
<b><u>Lung and Bronchus</u></b>									
Male	105	103.3	101.7	(83.1-123.1)					
Female	152	110.2	138.0	(116.9-161.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	8.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.2	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	3.8	159.2	(58.1-346.6)
Female	1	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	14	12.5	112.4	(61.4-188.5)
Female	0	0.1	nc	(nc-nc)	Female	6	10.8	55.5	(20.3-120.7)
<b><u>Lung and Bronchus</u></b>									
Male	3	1.6	nc	(nc-nc)					
Female	1	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	30.1	96.3	(64.5-138.3)	Male	37	18.2	203.0	(142.9-279.8)
Female	9	11.5	78.2	(35.7-148.5)	Female	25	14.2	176.6	(114.3-260.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.1	97.2	(31.3-226.9)	Male	6	5.8	103.6	(37.8-225.6)
Female	6	4.5	134.7	(49.2-293.1)	Female	5	5.0	99.5	(32.0-232.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	18	16.2	111.2	(65.9-175.8)
Female	116	111.4	104.2	(86.1-124.9)	Female	30	15.1	198.0	(133.6-282.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.4	nc	(nc-nc)	Male	16	12.4	129.4	(73.9-210.1)
<b><u>Colon / Rectum</u></b>					Female	6	6.3	95.6	(34.9-208.1)
Male	28	31.1	90.0	(59.8-130.2)	<b><u>Ovary</u></b>				
Female	40	34.3	116.5	(83.2-158.6)	Female	11	10.1	108.6	(54.1-194.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.5	nc	(nc-nc)	Male	5	10.3	48.4	(15.6-113.0)
Female	5	2.2	228.9	(73.8-534.2)	Female	10	11.7	85.7	(41.0-157.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	111	90.6	122.5	(100.7-147.5)
Female	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	6.8	131.7	(60.1-250.1)
Male	13	14.8	88.0	(46.8-150.5)	Female	1	4.5	nc	(nc-nc)
Female	11	9.2	119.8	(59.7-214.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.7	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	5	6.2	81.2	(26.2-189.5)
<b><u>Leukemia</u></b>					Female	29	17.9	162.2	(108.6-232.9)
Male	15	11.5	129.9	(72.6-214.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	8.9	134.6	(69.5-235.1)	Female	21	25.2	83.2	(51.5-127.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	9.5	nc	(nc-nc)	Male	367	368.7	99.5	(89.6-110.3)
Female	0	3.4	nc	(nc-nc)	Female	417	393.5	106.0	(96.0-116.6)
<b><u>Lung and Bronchus</u></b>									
Male	27	52.6	51.3	(33.8-74.7)					
Female	41	57.9	70.8	(50.8-96.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	16	9.5	169.1	(96.6-274.6)	Female	2	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	9	10.8	83.7	(38.2-158.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	1.8	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	43	43.8	98.1	(71.0-132.1)
Female	0	0.2	nc	(nc-nc)	Female	40	31.0	128.9	(92.1-175.6)
<b><u>Lung and Bronchus</u></b>									
Male	10	5.9	168.1	(80.5-309.2)					
Female	5	4.2	118.3	(38.1-276.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	13.2	166.5	(104.3-252.1)	Male	3	8.5	nc	(nc-nc)
Female	8	4.1	193.2	(83.2-380.7)	Female	9	6.1	146.6	(66.9-278.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	7	1.9	372.4	(149.2-767.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.6	131.4	(62.9-241.7)
Female	49	49.1	99.9	(73.9-132.1)	Female	8	5.8	136.8	(58.9-269.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.7	nc	(nc-nc)	Male	5	6.1	82.3	(26.5-192.0)
<b><u>Colon / Rectum</u></b>					Female	2	2.5	nc	(nc-nc)
Male	14	14.2	98.3	(53.7-164.9)	<b><u>Ovary</u></b>				
Female	14	12.5	112.2	(61.3-188.3)	Female	9	4.3	210.4	(96.0-399.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.5	201.1	(80.6-414.3)	Male	5	4.6	108.9	(35.1-254.1)
Female	1	0.8	nc	(nc-nc)	Female	5	4.1	123.3	(39.7-287.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	51	42.7	119.5	(89.0-157.2)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.1	nc	(nc-nc)
Male	12	7.2	167.0	(86.2-291.8)	Female	1	1.6	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	9.2	75.7	(30.3-156.0)
Male	6	5.2	115.7	(42.3-251.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	3.3	210.3	(84.3-433.4)	Female	11	10.9	100.6	(50.2-180.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	4.6	152.5	(61.1-314.2)	Male	192	171.5	112.0	(96.7-129.0)
Female	1	1.3	nc	(nc-nc)	Female	202	161.4	125.2	(108.5-143.7)
<b><u>Lung and Bronchus</u></b>									
Male	23	23.5	97.7	(61.9-146.7)					
Female	42	22.8	184.0	(132.6-248.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	19.1	89.2	(51.9-142.9)	Male	23	12.4	185.6	(117.6-278.4)
Female	10	6.9	145.5	(69.7-267.6)	Female	8	9.7	82.3	(35.4-162.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	5	3.9	127.4	(41.1-297.3)
Female	4	3.0	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	11	11.1	98.9	(49.3-176.9)
Female	86	76.9	111.8	(89.4-138.1)	Female	9	9.6	93.6	(42.7-177.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.6	nc	(nc-nc)	Male	12	9.1	132.2	(68.2-230.9)
<b><u>Colon / Rectum</u></b>					Female	4	4.1	nc	(nc-nc)
Male	14	21.0	66.8	(36.5-112.1)	<b><u>Ovary</u></b>				
Female	25	20.9	119.5	(77.3-176.4)	Female	7	6.8	103.0	(41.3-212.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	5.1	157.5	(67.8-310.3)	Male	10	6.7	148.5	(71.1-273.2)
Female	1	1.3	nc	(nc-nc)	Female	4	6.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	63	63.8	98.7	(75.8-126.3)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.5	nc	(nc-nc)
Male	7	10.6	65.8	(26.3-135.5)	Female	3	2.7	nc	(nc-nc)
Female	6	6.1	99.0	(36.2-215.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.4	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	14.1	49.5	(19.8-102.0)
Male	10	7.7	130.1	(62.3-239.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.6	nc	(nc-nc)	Female	30	17.2	174.5	(117.7-249.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.8	73.9	(23.8-172.4)	Male	252	251.8	100.1	(88.1-113.2)
Female	3	2.2	nc	(nc-nc)	Female	273	258.7	105.5	(93.4-118.8)
<b><u>Lung and Bronchus</u></b>									
Male	33	34.1	96.7	(66.5-135.8)					
Female	29	36.3	80.0	(53.6-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.9	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	8	10.0	80.2	(34.5-158.0)	Female	2	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	7	10.4	67.0	(26.8-138.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.0	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.6	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	28	40.1	69.8	(46.4-100.9)
Female	0	0.2	nc	(nc-nc)	Female	33	30.8	107.1	(73.7-150.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	5.5	nc	(nc-nc)					
Female	5	3.9	127.6	(41.1-297.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	13.8	123.5	(71.9-197.7)	Male	10	9.2	109.0	(52.2-200.4)
Female	2	4.9	nc	(nc-nc)	Female	6	7.4	81.0	(29.6-176.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	2.9	312.7	(142.7-593.6)	Male	4	2.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	8.3	133.3	(66.5-238.5)
Female	71	60.2	117.9	(92.1-148.7)	Female	4	7.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.0	nc	(nc-nc)	Male	8	7.0	113.9	(49.1-224.5)
<b><u>Colon / Rectum</u></b>					Female	4	3.1	nc	(nc-nc)
Male	16	15.6	102.3	(58.4-166.2)	<b><u>Ovary</u></b>				
Female	14	15.0	93.0	(50.8-156.1)	Female	3	5.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.8	182.9	(73.3-376.8)	Male	4	5.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	68	49.9	136.3	(105.8-172.8)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.3	nc	(nc-nc)
Male	11	8.1	135.4	(67.5-242.2)	Female	1	1.9	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.8	271.4	(87.5-633.4)
Male	3	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	11.1	135.3	(75.7-223.2)
Male	5	5.7	87.8	(28.3-204.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.1	nc	(nc-nc)	Female	21	13.8	152.3	(94.3-232.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.2	nc	(nc-nc)	Male	223	189.4	117.7	(102.8-134.2)
Female	1	1.6	nc	(nc-nc)	Female	196	195.7	100.1	(86.6-115.2)
<b><u>Lung and Bronchus</u></b>									
Male	15	24.9	60.2	(33.7-99.4)					
Female	24	26.6	90.2	(57.8-134.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	39.9	75.2	(50.8-107.4)	Male	20	24.8	80.8	(49.3-124.8)
Female	13	16.2	80.1	(42.6-136.9)	Female	10	22.1	45.2	(21.6-83.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	7.6	118.9	(54.3-225.8)	Male	4	7.7	nc	(nc-nc)
Female	4	7.0	nc	(nc-nc)	Female	1	7.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	19	22.3	85.0	(51.2-132.8)
Female	126	166.3	75.7	(63.1-90.2)	Female	17	22.0	77.4	(45.1-124.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.7	158.3	(72.2-300.4)	Male	26	16.9	153.7	(100.3-225.2)
<b><u>Colon / Rectum</u></b>					Female	4	9.0	nc	(nc-nc)
Male	40	42.2	94.7	(67.6-128.9)	<b><u>Ovary</u></b>				
Female	49	48.9	100.2	(74.1-132.4)	Female	13	15.0	86.5	(46.0-147.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	9.9	80.9	(34.8-159.3)	Male	15	13.7	109.7	(61.4-181.0)
Female	2	3.1	nc	(nc-nc)	Female	23	16.4	139.9	(88.7-210.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	113	120.9	93.4	(77.0-112.3)
Female	5	2.8	178.1	(57.4-415.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	9.2	54.4	(17.5-127.0)
Male	19	20.2	93.9	(56.5-146.6)	Female	10	6.4	156.6	(75.0-288.1)
Female	6	13.6	44.1	(16.1-96.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	5.7	nc	(nc-nc)
Male	8	5.7	140.3	(60.4-276.6)	<b><u>Thyroid</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	1	9.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	22	31.1	70.7	(44.3-107.0)
Male	10	16.1	62.2	(29.8-114.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	13.5	66.8	(30.5-126.8)	Female	45	36.8	122.2	(89.1-163.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	25	12.7	196.6	(127.2-290.3)	Male	486	499.5	97.3	(88.8-106.3)
Female	7	4.9	142.4	(57.0-293.4)	Female	493	581.7	84.7	(77.4-92.6)
<b><u>Lung and Bronchus</u></b>									
Male	78	68.8	113.4	(89.6-141.5)					
Female	65	82.5	78.8	(60.8-100.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.5	76.7	(24.7-179.0)	Male	6	4.1	146.0	(53.3-317.8)
Female	2	2.2	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	26	24.5	106.3	(69.4-155.7)	Female	0	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	4	7.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	9	7.0	128.1	(58.5-243.2)	Female	1	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	26	19.4	134.0	(87.5-196.3)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.5	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.5	133.6	(48.8-290.9)
Male	3	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.8	nc	(nc-nc)	Female	8	5.4	149.3	(64.3-294.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	92	82.5	111.5	(89.9-136.7)
Female	0	0.7	nc	(nc-nc)	Female	80	82.9	96.4	(76.5-120.0)
<b><u>Lung and Bronchus</u></b>									
Male	15	10.7	140.3	(78.5-231.4)					
Female	12	11.3	106.0	(54.7-185.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	11.7	102.9	(53.1-179.8)	Male	13	8.3	156.4	(83.2-267.4)
Female	5	4.1	120.9	(38.9-282.1)	Female	11	7.0	156.6	(78.1-280.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	2.9	347.9	(166.5-639.8)	Male	2	2.6	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.6	79.4	(29.0-172.9)
Female	54	57.6	93.8	(70.5-122.4)	Female	7	6.3	111.0	(44.5-228.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	7	6.7	105.1	(42.1-216.5)
<b><u>Colon / Rectum</u></b>					Female	1	2.7	nc	(nc-nc)
Male	5	14.0	35.8	(11.5-83.4)	<b><u>Ovary</u></b>				
Female	10	13.2	75.9	(36.3-139.6)	Female	2	4.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	6	4.1	147.5	(53.8-321.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	54	45.1	119.8	(90.0-156.4)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.9	171.3	(55.2-399.9)
Male	5	7.7	65.3	(21.0-152.3)	Female	0	1.7	nc	(nc-nc)
Female	1	4.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.0	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	5	3.8	130.6	(42.1-304.7)
<b><u>Leukemia</u></b>					Female	16	11.7	137.3	(78.4-223.0)
Male	4	5.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	3.8	nc	(nc-nc)	Female	11	12.6	87.4	(43.6-156.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.8	nc	(nc-nc)	Male	167	170.7	97.8	(83.5-113.8)
Female	2	1.4	nc	(nc-nc)	Female	163	180.1	90.5	(77.1-105.5)
<b><u>Lung and Bronchus</u></b>									
Male	13	21.4	60.8	(32.3-103.9)					
Female	18	23.2	77.7	(46.0-122.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.6	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	2.8	177.1	(57.1-413.4)
Female	18	18.1	99.6	(59.0-157.4)	Female	1	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	7	0.9	797.4	(319.5-1643.1)
Male	0	5.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	4.3	139.3	(50.9-303.3)	Female	3	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	16.1	68.2	(34.0-122.1)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.6	139.7	(45.0-326.0)
Male	1	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	42	63.4	66.3	(47.7-89.6)
Female	0	0.4	nc	(nc-nc)	Female	63	56.4	111.7	(85.9-143.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	8.5	nc	(nc-nc)					
Female	9	7.0	127.8	(58.3-242.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	23.1	99.7	(63.2-149.6)	Male	11	14.8	74.1	(36.9-132.6)
Female	8	7.9	101.7	(43.8-200.5)	Female	10	11.1	89.8	(43.0-165.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	4.4	205.5	(93.8-390.1)	Male	3	4.7	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	6	13.2	45.6	(16.6-99.2)
Female	81	89.3	90.7	(72.0-112.7)	Female	7	10.9	64.1	(25.7-132.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	12	10.7	112.5	(58.1-196.6)
<b><u>Colon / Rectum</u></b>					Female	5	4.6	108.1	(34.9-252.4)
Male	31	24.6	126.1	(85.7-179.0)	<b><u>Ovary</u></b>				
Female	28	22.9	122.4	(81.3-176.9)	Female	9	7.8	115.6	(52.8-219.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.2	80.8	(26.0-188.5)	Male	4	8.2	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	5	7.8	64.3	(20.7-150.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	77	80.5	95.6	(75.5-119.5)
Female	2	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.4	92.8	(29.9-216.5)
Male	7	12.8	54.6	(21.9-112.5)	Female	5	2.9	170.8	(55.0-398.5)
Female	9	7.1	126.7	(57.8-240.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.8	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	27	16.1	167.8	(110.5-244.1)
Male	7	9.1	76.5	(30.7-157.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	6.3	nc	(nc-nc)	Female	27	20.5	131.5	(86.6-191.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	7.9	76.1	(27.8-165.6)	Male	265	305.4	86.8	(76.6-97.9)
Female	2	2.5	nc	(nc-nc)	Female	292	297.9	98.0	(87.1-109.9)
<b><u>Lung and Bronchus</u></b>									
Male	31	42.4	73.2	(49.7-103.9)					
Female	36	43.3	83.1	(58.2-115.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hull

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	12.5	128.0	(73.1-207.8)	Male	15	8.1	185.1	(103.5-305.4)
Female	5	5.0	99.6	(32.1-232.3)	Female	11	7.2	153.5	(76.5-274.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	5	7.2	69.8	(22.5-162.9)
Female	56	58.8	95.3	(72.0-123.8)	Female	9	7.1	127.1	(58.0-241.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	3.1	163.8	(52.8-382.3)
Male	13	13.5	96.3	(51.2-164.7)	<b><u>Ovary</u></b>				
Female	9	15.0	60.0	(27.4-113.9)	Female	4	5.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	8	4.9	162.8	(70.1-320.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	45	45.2	99.5	(72.6-133.1)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.0	nc	(nc-nc)
Male	9	7.1	127.4	(58.1-241.9)	Female	1	1.9	nc	(nc-nc)
Female	5	4.6	108.5	(35.0-253.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.3	381.2	(122.9-889.7)
Male	5	2.1	238.9	(77.0-557.4)	<b><u>Thyroid</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	10.2	49.1	(15.8-114.5)
Male	2	4.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.9	nc	(nc-nc)	Female	16	13.7	116.4	(66.5-189.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	4.7	301.0	(164.4-505.0)	Male	194	168.3	115.2	(99.6-132.7)
Female	0	1.7	nc	(nc-nc)	Female	194	193.4	100.3	(86.7-115.5)
<b><u>Lung and Bronchus</u></b>									
Male	24	23.2	103.5	(66.3-154.0)					
Female	30	27.8	107.8	(72.7-153.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	11	9.0	122.8	(61.2-219.8)	Female	2	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	2.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	3	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	1.7	nc	(nc-nc)
Male	3	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	34	27.7	122.9	(85.1-171.7)
Female	1	0.2	nc	(nc-nc)	Female	34	29.0	117.4	(81.3-164.1)
<b><u>Lung and Bronchus</u></b>									
Male	8	3.5	231.0	(99.5-455.2)					
Female	6	4.0	148.9	(54.4-324.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	19.1	115.3	(72.2-174.5)	Male	15	12.0	124.9	(69.8-205.9)
Female	10	6.7	149.5	(71.6-274.9)	Female	10	8.5	117.6	(56.3-216.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	8	10.6	75.2	(32.4-148.1)
Female	86	69.7	123.4	(98.7-152.5)	Female	8	9.0	88.6	(38.2-174.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	8	8.7	91.5	(39.4-180.3)
<b><u>Colon / Rectum</u></b>					Female	7	3.8	185.3	(74.2-381.8)
Male	13	20.5	63.6	(33.8-108.7)	<b><u>Ovary</u></b>				
Female	15	19.8	75.8	(42.4-125.0)	Female	8	6.2	129.3	(55.7-254.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	5.1	177.9	(81.2-337.8)	Male	7	6.7	103.8	(41.6-213.9)
Female	3	1.3	nc	(nc-nc)	Female	6	6.7	89.4	(32.7-194.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	81	65.4	123.9	(98.4-154.0)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.5	nc	(nc-nc)
Male	7	10.2	68.5	(27.4-141.1)	Female	5	2.5	196.4	(63.3-458.3)
Female	6	5.6	106.9	(39.0-232.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.8	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	11.0	109.3	(56.4-190.9)
Male	3	7.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.1	117.8	(43.0-256.5)	Female	12	16.1	74.5	(38.5-130.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.6	nc	(nc-nc)	Male	242	248.2	97.5	(85.6-110.6)
Female	5	2.1	240.3	(77.4-560.8)	Female	248	238.0	104.2	(91.6-118.0)
<b><u>Lung and Bronchus</u></b>									
Male	24	34.4	69.8	(44.7-103.9)					
Female	29	35.1	82.6	(55.3-118.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	14.6	89.3	(47.5-152.7)	Male	13	9.3	139.9	(74.4-239.3)
Female	6	5.5	108.8	(39.7-236.8)	Female	10	7.5	133.1	(63.7-244.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	8.2	nc	(nc-nc)
Female	60	60.2	99.8	(76.1-128.4)	Female	8	7.6	104.9	(45.2-206.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	6	6.6	90.9	(33.2-198.0)
<b><u>Colon / Rectum</u></b>					Female	3	3.2	nc	(nc-nc)
Male	14	15.5	90.3	(49.3-151.5)	<b><u>Ovary</u></b>				
Female	14	16.9	82.9	(45.3-139.1)	Female	2	5.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.8	nc	(nc-nc)	Male	14	5.1	276.5	(151.1-464.0)
Female	5	1.0	476.5	(153.6-1112.0)	Female	10	5.5	180.7	(86.5-332.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	40	46.8	85.6	(61.1-116.5)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.4	146.7	(47.3-342.2)
Male	9	7.8	116.1	(53.0-220.4)	Female	1	2.2	nc	(nc-nc)
Female	2	4.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.7	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	14	10.6	131.6	(71.9-220.8)
Male	6	5.7	104.7	(38.2-227.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.4	135.9	(49.6-295.9)	Female	17	13.3	127.8	(74.4-204.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	5.1	nc	(nc-nc)	Male	173	187.5	92.3	(79.0-107.1)
Female	1	1.7	nc	(nc-nc)	Female	218	203.4	107.2	(93.4-122.4)
<b><u>Lung and Bronchus</u></b>									
Male	27	26.1	103.6	(68.3-150.8)					
Female	29	28.7	101.2	(67.7-145.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	12.0	99.8	(51.5-174.3)	Male	8	7.9	101.3	(43.6-199.6)
Female	5	3.7	135.2	(43.6-315.4)	Female	4	5.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.0	99.9	(40.0-205.9)
Female	55	48.1	114.5	(86.2-149.0)	Female	4	5.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	6	6.1	98.8	(36.1-215.2)
<b><u>Colon / Rectum</u></b>					Female	5	2.4	206.5	(66.5-481.8)
Male	13	13.1	99.2	(52.8-169.7)	<b><u>Ovary</u></b>				
Female	10	11.3	88.2	(42.2-162.2)	Female	4	4.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.4	147.0	(47.4-343.0)	Male	4	4.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	3.7	135.9	(43.8-317.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	40	45.8	87.4	(62.4-119.0)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.9	nc	(nc-nc)
Male	5	7.0	71.5	(23.0-166.8)	Female	0	1.4	nc	(nc-nc)
Female	5	3.6	138.1	(44.5-322.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	9.0	166.8	(93.3-275.2)
Male	3	4.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.2	nc	(nc-nc)	Female	14	11.3	124.3	(67.9-208.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	147	165.8	88.7	(74.9-104.2)
Female	2	1.3	nc	(nc-nc)	Female	167	153.5	108.8	(92.9-126.6)
<b><u>Lung and Bronchus</u></b>									
Male	13	22.3	58.3	(31.0-99.8)					
Female	19	20.5	92.8	(55.9-145.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	8.4	119.4	(57.2-219.6)	Male	7	5.7	122.3	(49.0-252.0)
Female	3	2.4	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.1	117.4	(42.9-255.6)
Female	29	28.2	102.7	(68.8-147.6)	Female	2	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.5	nc	(nc-nc)
Male	6	9.2	65.6	(23.9-142.7)	<b><u>Ovary</u></b>				
Female	2	7.2	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	39	31.1	125.2	(89.0-171.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.0	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.7	nc	(nc-nc)
Male	4	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.3	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.0	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	118	117.2	100.7	(83.3-120.6)
Female	2	0.8	nc	(nc-nc)	Female	77	93.0	82.8	(65.3-103.4)
<b><u>Lung and Bronchus</u></b>									
Male	9	15.4	58.4	(26.6-110.8)					
Female	9	12.8	70.2	(32.0-133.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	6	2.0	293.2	(107.1-638.2)
Female	0	1.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	7	12.0	58.5	(23.4-120.6)	Female	2	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	8	12.4	64.3	(27.7-126.8)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.7	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	2.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.8	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	44	43.3	101.5	(73.8-136.3)
Female	0	0.3	nc	(nc-nc)	Female	27	39.2	68.9	(45.4-100.2)
<b><u>Lung and Bronchus</u></b>									
Male	8	5.5	144.8	(62.3-285.3)					
Female	4	5.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	52.0	94.3	(69.7-124.6)	Male	13	35.8	36.3	(19.3-62.1)
Female	17	20.7	82.1	(47.8-131.4)	Female	10	34.0	29.4	(14.1-54.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	12.9	69.9	(31.9-132.7)	Male	12	10.8	110.7	(57.2-193.5)
Female	7	11.3	62.1	(24.9-127.9)	Female	18	9.5	189.7	(112.4-299.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	29	32.5	89.1	(59.7-128.0)
Female	176	251.3	70.0	(60.1-81.2)	Female	32	30.6	104.7	(71.6-147.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	15	9.8	152.9	(85.5-252.2)	Male	31	26.2	118.1	(80.3-167.7)
<b><u>Colon / Rectum</u></b>					Female	12	13.0	92.3	(47.6-161.2)
Male	60	58.8	102.0	(77.8-131.3)	<b><u>Ovary</u></b>				
Female	55	64.3	85.6	(64.4-111.4)	Female	12	22.3	53.7	(27.7-93.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	14.1	63.7	(29.0-120.9)	Male	17	18.6	91.3	(53.1-146.1)
Female	9	4.1	221.6	(101.1-420.7)	Female	13	20.8	62.4	(33.2-106.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	6.0	nc	(nc-nc)	Male	238	179.2	132.8	(116.5-150.8)
Female	3	5.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	12.5	159.8	(97.6-246.8)
Male	22	30.9	71.2	(44.6-107.9)	Female	14	8.3	168.5	(92.0-282.7)
Female	19	19.5	97.3	(58.5-151.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	13	12.0	108.6	(57.8-185.7)
Male	9	8.2	109.4	(49.9-207.8)	<b><u>Thyroid</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	15	15.9	94.5	(52.8-155.8)
<b><u>Leukemia</u></b>					Female	65	55.4	117.4	(90.6-149.6)
Male	16	24.0	66.8	(38.1-108.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	19.2	109.4	(67.7-167.2)	Female	47	56.0	83.9	(61.7-111.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	34	19.2	177.5	(122.9-248.1)	Male	747	721.9	103.5	(96.2-111.2)
Female	15	6.8	220.6	(123.4-363.8)	Female	715	839.5	85.2	(79.0-91.7)
<b><u>Lung and Bronchus</u></b>									
Male	89	93.1	95.6	(76.8-117.7)					
Female	88	108.6	81.0	(65.0-99.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lee

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	8.7	160.8	(87.8-269.8)	Male	7	5.4	130.3	(52.2-268.5)
Female	1	2.5	nc	(nc-nc)	Female	9	3.5	260.0	(118.6-493.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	5	1.1	454.3	(146.4-1060.1)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.7	nc	(nc-nc)
Female	21	28.0	75.1	(46.5-114.8)	Female	3	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	5	8.8	56.5	(18.2-131.9)	<b><u>Ovary</u></b>				
Female	6	7.1	84.9	(31.0-184.8)	Female	1	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	29	29.5	98.2	(65.8-141.1)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.0	nc	(nc-nc)
Male	5	4.5	111.4	(35.9-260.0)	Female	3	0.9	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.9	102.6	(33.1-239.4)
Male	2	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	112	111.4	100.5	(82.8-120.9)
Female	3	0.8	nc	(nc-nc)	Female	96	93.5	102.6	(83.1-125.4)
<b><u>Lung and Bronchus</u></b>									
Male	18	15.8	114.0	(67.5-180.1)					
Female	20	13.7	146.4	(89.4-226.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	10.6	85.1	(38.8-161.6)	Male	12	7.2	166.2	(85.8-290.4)
Female	4	4.6	nc	(nc-nc)	Female	8	6.5	124.0	(53.4-244.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	49	50.1	97.7	(72.3-129.2)	Female	5	6.4	78.5	(25.3-183.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.7	nc	(nc-nc)	Male	7	5.5	128.2	(51.4-264.2)
<b><u>Colon / Rectum</u></b>					Female	4	2.7	nc	(nc-nc)
Male	9	11.9	75.6	(34.5-143.6)	<b><u>Ovary</u></b>				
Female	10	13.5	74.2	(35.5-136.6)	Female	5	4.5	111.4	(35.9-260.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	7	4.5	155.8	(62.4-320.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	29	38.9	74.5	(49.9-107.0)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.6	nc	(nc-nc)
Male	6	6.3	94.5	(34.5-205.8)	Female	0	1.7	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.7	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	9.3	nc	(nc-nc)
Male	10	4.4	229.5	(109.9-422.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.6	nc	(nc-nc)	Female	14	11.8	118.9	(64.9-199.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.1	nc	(nc-nc)	Male	141	147.6	95.5	(80.4-112.7)
Female	0	1.5	nc	(nc-nc)	Female	157	170.5	92.1	(78.2-107.6)
<b><u>Lung and Bronchus</u></b>									
Male	23	19.6	117.1	(74.2-175.7)					
Female	21	24.5	85.8	(53.1-131.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	10.3	165.5	(96.3-264.9)	Male	8	5.6	143.8	(61.9-283.4)
Female	1	3.9	nc	(nc-nc)	Female	5	4.1	121.1	(39.0-282.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	34	32.4	104.9	(72.6-146.6)	Female	4	4.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	18	9.7	184.9	(109.5-292.2)	<b><u>Ovary</u></b>				
Female	16	11.3	141.1	(80.6-229.2)	Female	4	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	25	27.7	90.4	(58.5-133.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.2	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.2	nc	(nc-nc)
Male	5	3.6	140.0	(45.1-326.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.8	nc	(nc-nc)	Female	9	7.5	119.3	(54.4-226.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	111	114.1	97.3	(80.0-117.2)
Female	2	1.1	nc	(nc-nc)	Female	117	121.3	96.4	(79.8-115.6)
<b><u>Lung and Bronchus</u></b>									
Male	11	17.0	64.9	(32.3-116.1)					
Female	15	19.1	78.7	(44.0-129.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	48.3	111.7	(83.9-145.8)	Male	23	30.4	75.7	(48.0-113.6)
Female	29	15.6	186.2	(124.7-267.4)	Female	20	22.3	89.8	(54.8-138.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	8.8	68.4	(25.0-148.8)	Male	9	9.6	94.0	(42.9-178.5)
Female	7	6.9	101.0	(40.4-208.0)	Female	4	7.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	29	27.3	106.3	(71.2-152.7)
Female	164	172.0	95.3	(81.3-111.1)	Female	25	21.7	115.3	(74.6-170.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	6.0	133.0	(57.3-262.1)	Male	21	21.1	99.3	(61.5-151.8)
<b><u>Colon / Rectum</u></b>					Female	9	9.2	98.3	(44.9-186.7)
Male	41	51.8	79.1	(56.8-107.4)	<b><u>Ovary</u></b>				
Female	37	47.9	77.2	(54.4-106.5)	Female	28	15.4	182.1	(121.0-263.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	12.3	97.9	(50.5-171.0)	Male	13	16.7	78.0	(41.5-133.5)
Female	2	3.0	nc	(nc-nc)	Female	15	15.6	96.3	(53.9-158.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	149	149.1	99.9	(84.5-117.3)
Female	4	2.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	11.2	116.1	(61.8-198.6)
Male	25	25.2	99.4	(64.3-146.7)	Female	5	6.1	81.4	(26.2-189.8)
Female	15	13.7	109.8	(61.4-181.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	6.3	nc	(nc-nc)
Male	8	7.0	113.7	(49.0-224.1)	<b><u>Thyroid</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	9	11.4	78.7	(35.9-149.5)
<b><u>Leukemia</u></b>					Female	19	32.8	57.9	(34.8-90.4)
Male	18	19.0	95.0	(56.3-150.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	12.9	85.4	(42.6-152.9)	Female	35	38.2	91.6	(63.8-127.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	15.8	44.4	(17.8-91.6)	Male	575	610.1	94.2	(86.7-102.3)
Female	0	4.9	nc	(nc-nc)	Female	563	583.8	96.4	(88.6-104.7)
<b><u>Lung and Bronchus</u></b>									
Male	91	84.0	108.3	(87.2-133.0)					
Female	77	80.6	95.5	(75.4-119.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;